| Literature DB >> 29556267 |
Shifeng Wu1, Xin Sun2, Wei Wu3, Dazhi Shi4, Tao Jiang5.
Abstract
The aim of the study was to investigate the effects of revascularization in treating patients with thromboangiitis obliterans (TAO), to analyze the prognosis of TAO. The treatment group comprised 32 patients with TAO of lower limbs who were selected between March 2012 and March 2017. Patients in the treatment group were treated with revascularization (vascular bypass surgery, catheter-directed thrombolysis and angioplasty, endovascular angioplasty + stening, thromboectomy and/or endarterectomy) + Western medicine. Another 33 patients with TAO who were treated with Western medicine alone comprised the control group. Treatment outcomes were compared between the groups. Serum levels of interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) were also detected and compared between the groups. Multivariate analysis was performed to identify the factors related to prognosis. Compared with control group, treatment outcomes were significantly better in the treatment group (P<0.05). After treatment, the serum levels of IL-6, IL-8 and TNF-α significantly decreased in both groups, and the decrease in the treatment group was more significant (P<0.01). Multivariate analysis revealed that vascular bypass surgery and preoperative ischemic degree are associated with treatment effect. Our results show that revascularization treatment of TAO is conducive to clinical symptoms and dysfunction of inflammatory cytokines, and the type of surgery and surgical timing significantly affect treatment outcomes.Entities:
Keywords: IL-6; IL-8; TNF-α; revascularization; thromboangiitis obliterans
Year: 2018 PMID: 29556267 PMCID: PMC5844100 DOI: 10.3892/etm.2018.5877
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Comparison of general clinical data between two groups of patients.
| General information | Treatment group (n=32) | Control group (n=33) | t/χ2 value | P-value |
|---|---|---|---|---|
| Age (years) | 39.18±7.45 | 39.21±7.38 | 1.729 | 0.168 |
| Course of illness | 2.65±0.58 | 2.73±0.47 | 1.867 | 0.115 |
| BMI (kg/m2) | 24.21±4.35 | 24.34±3.93 | 1.645 | 0.186 |
| Stages [n (%)] | 1.912 | 0.089 | ||
| Local ischemia | 23 | 24 | ||
| Nutritional disorder | 8 | 8 | ||
| Gangrene | 1 | 1 | ||
| Main symptoms [n (%)] | 1.981 | 0.094 | ||
| Intermittent claudication | 23 | 24 | ||
| Rest pain | 9 | 9 |
Comparison of treatment outcomes between two groups.
| Efficacy | Treatment group (n=32) | Control group (n=33) | χ2 value | P-value |
|---|---|---|---|---|
| Cure | 26 | 21 | ||
| Markedly effective | 2 | 3 | 3.265 | 0.038 |
| Effective | 2 | 3 | ||
| Ineffective | 2 | 6 | 6.743 | 0.002 |
| Limb salvage rate | 90.63% | 81.82% | 4.125 | 0.023 |
Changes in inflammatory cytokines in the two groups (ng/l, mean ± SD).
| Treatment group (n=32) | Control group (n=33) | |||
|---|---|---|---|---|
| Observation indicators | Before treatment | After treatment | Before treatment | After treatment |
| IL-6 | 4.32±2.30 | 1.24±2.35[ | 4.28±2.34 | 2.19±2.27[ |
| IL-8 | 843.21±95.32 | 250.76±78.12[ | 846.15±92.56 | 607.98±74.33[ |
| TNF-α | 4.57±2.12 | 1.64±1.53[ | 4.55±2.14 | 3.05±1.60[ |
P<0.05, compared with pre-treatment level
P<0.05 compared with control group.
Regression analysis and the relationship between various factors and prognosis.
| Variables | Regression coefficients | Standard error | Wald value | Degrees of freedom | P-value | OR value |
|---|---|---|---|---|---|---|
| Treatment methods | 3.023 | 1.521 | 4.073 | 1 | 0.032 | 20.623 |
| Smoking | 0.948 | 1.398 | 0.434 | 1 | 0.481 | 2.812 |
| Age | 0.385 | 1.278 | 0.089 | 1 | 0.716 | 1.476 |
| Degree of ischemia | −3.102 | 1.532 | 4.121 | 1 | 0.035 | 0.451 |